METHOD FOR PREDICTING RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER Russian patent published in 2023 - IPC G01N33/50 G01N33/68 A61B5/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to predict early recurrence of non-muscle-invasive bladder cancer (NMIBC). The method includes conducting enzyme immunoassay to determine the cytokine composition of tumor tissues and peritumoral zone: IL-1β, IL-6, IL-10, IL-18, TNF-α, INF-γ, IL-8 chemokine. At the following level of expression of pro-inflammatory cytokines in tumor tissue: IL-6≥ 9.1 pg/ml, IL-8 > 24.6 pg/ml, TNF-α≥ 10.9 pg/ml, IL-1β≥ 25.6 pg/ml, IL-18≥ 36.0 pg/ml and at the following level of expression of pro-inflammatory cytokines in the peritumoral zone: IL-6 > 6.6 pg/ml, IL-8 > 0.7 pg/ml, TNF-α > 5.2 pg/ml, IL-1β > 18.2 pg / ml, IL-18 > 31.1 pg/ml and with an increased level of expression of anti-inflammatory cytokines in the peritumoral zone: IL-10 > 6.8 pg/ml, INF-γ > 17.5 pg/ml and in tumor tissue: IL-10 > 7.5 pg/ml, INF-γ≥ 9.9 pg/mg, the development of relapse after complex treatment is predicted in the next 6–9 months. The use of the method will allow to predict the risks of recurrence of the disease, and will also help to evaluate the results of the complex treatment.

EFFECT: basis for determining the likelihood of recurrence mechanisms and response to therapy in non-muscle-invasive bladder cancer.

1 cl, 2 tbl, 2 ex